LaserACE® Safety & Efficacy

LaserACE® improves uncorrected intermediate and near visual acuity as well as distance corrected near and intermediate visual acuity with stable distance vision.

LaserACE® Stability of Distance Vision

In this single arm clinical trial 24 month study 100% of the patients had no statistically significant change in distance vision after the procedure through 24 months.

LaserACE® Binocular Uncorrected Visual Acuity (UVA)

In an early pilot study of LaserACE®, visual acuities were measured using standard early treatment diabetic retinopathy study (ETDRS) charts. Patient near visual acuity showed a statistically significant improvement of up to 8 lines following LaserACE® treatment. Patient uncorrected intermediate and distance visual acuities improved or remained stable after the LaserACE® treatment. Data collection is ongoing.

Accommodative Restoration Stable for Many Years

The accommodation improvements of LaserACE® appears to be stable over time. In a pilot study, effective range of focus (EROF), true physiological accommodation, and pseudoaccommodation were measured in 6 eyes of 3 patients (average age 59.3 years) for up to 13 years postoperatively after LaserACE® treatment. Measurements were done using wavefront aberrometry with the iTrace dynamic aberrometer (Tracey Technologies, Houston, TX). The EROF is the range of focus with acceptable blur and is the sum of the true physiological accommodation and the pseudoaccommodation.

Stereopsis showed improvement over time through 24 months

LaserACE® Mean Stereopsis improved from less than 70” than 60” at 1 yr and continued to improve at 24mos. This is unique to LaserACE® Procedure. Most corneal based presbyopic treatments reduce stereopsis and can lead to asthenopia.

IOP Reduction over baseline through 24 months

Patient Quality of Life Improvement

as per the CatQuest-9sf Standardized Questionnaire at 24 months as Measured by a Standardized Questionnaire (CATQuest 9sf) Before & After LaserACE®.

Safety Profile for LaserACE® Procedure

The procedure spares conjunctival tissue and preserves tissue via small transconjunctival 225um spot size. There is minimal risk due to the procedure being performed off the visual axis. The LaserACE® procedure can therefore improve visual function without touching the optics of the eye. This avoids any side effects such as halos, starbursts and glare that can occur when the eyes natural optics are modified to create multimodality for various distances to of hypotony with a trained surgeon. The proprietary collagen matrix allows for easy intraoperative management of any micro perforation with no lasting impact.

LaserACE® IRB Registered Taiwan Clinical Trial Visual Outcomes

The 24 month results from a single arm Taiwan Clinical Trial at Chang Gung Memorial Hospital for patients 40 years or older with presbyopia requiring a minimum of 1.5D reading add and best corrected distance of 20/40 or better in otherwise health eyes have been analyzed. All patients achieved improvement of near and intermediate vision. Visual Function and acuity improvement had clinical significance. The subjects gained an average of 1.5D added accommodative reading power after the procedure. No statistical change was noted in UCDVA post operatively. Stereoacuity was improved by the procedure. Patient satisfaction was high post operatively and sustained over 24 months in this group of Asian eyes. Preliminary results of the Taiwan IRB monitored clinical trial of the LaserACE® procedure utilizing the Er:YAG laser appears to show promise for restoring range of visual performance for near and intermediate visual tasks without compromising distance vision and without touching the visual axis.
Note: LaserACE® is not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.

Ace Vision Group, Inc.
39655 Eureka Dr, Newark, CA 94560
Telephone: 234-738-4074
234-738-4074

Ace Vision See Life NaturallyTM, LaserACE® and VisioLite® are registered trademarks of Ace Vision Group, Inc. All rights reserved. 2008-2019.